Sutro Biopharma Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 1.45
Dividend & YieldN/A$ (N/A)
Beta 1
Market capitalization 420.15M
Operating cash flow 5.83M
ESG Scores unknown

Company description

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Sector: Healthcare - Industry: Biotechnology

Financial Ratios
Quick Ratio5.24
Working Capital-0.6
Return On Equity-0.42
Debt To Equity0.06
Fixed Asset Ratio-0.01
Fixed Interest Cover-30.75

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 42.51M -17.93M -15.9M -8.77M
Total Cashflows From Investing Activities -80.19M -51.13M 604k -97.31M
Net Borrowings -5M -5M 15M
Total Cash From Financing Activities 170.78M -4.18M 269.25M 3.26M
Change To Operating Activities 957k -1.52M 3.68M -1.95M
Issuance Of Stock 84.78M 1.44M 254.56M 4.25M
Net Income -35.32M -55.74M -32.13M -105.54M
Change In Cash 103.28M -120.34M 202.05M -175.74M
Effect Of Exchange Rate
Total Cash From Operating Activities 12.68M -65.02M -67.8M -81.68M
Depreciation 4.54M 4.78M 4.3M 4.84M
Change To Account Receivables -865k -3.81M 739k -6.89M
Other Cashflows From Financing Activities 1M -327k
Change To Netincome 855k 9.21M -28.48M 36.63M
Capital Expenditures -1.56M -3.48M -7.13M -15.32M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development
Income Before Tax -35.32M -55.74M -32.13M -105.54M
Net Income -35.32M -55.74M -32.13M -105.54M
Selling General Administrative 21.38M 32.59M 36.82M 56M
Gross Profit -15.84M -22.88M -34.24M -42.52M
Ebit -37.36M -55.62M -71.13M -98.42M
Operating Income -37.36M -55.62M -71.13M -98.42M
Interest Expense -1.8M -1.3M -2.8M -3.2M
Income Tax Expense
Total Revenue 38.42M 42.74M 42.72M 61.88M
Cost Of Revenue 54.26M 65.61M 76.96M 104.4M
Total Other Income ExpenseNet 2.04M -123k 39.01M -7.12M
Net Income From Continuing Ops -35.32M -55.74M -32.13M -105.54M
Net Income Applicable To Common Shares -35.32M -55.74M -32.13M -105.54M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 91.6M 58.58M 62.06M 88.84M
Total Stockholder Equity 131.54M 97.79M 332.05M 252.56M
Other Current Liabilities 22.42M 20.37M 15.23M 8.58M
Total Assets 223.14M 156.37M 394.11M 341.41M
Common Stock 23k 23k 46k 46k
Other Current Assets
Retained Earnings -150.33M -195.75M -227.87M -333.41M
Treasury Stock -47k 165k 129k -314k
Cash 125.3M 4.96M 206.15M 30.41M
Total Current Liabilities 36.42M 32.97M 29.6M 41.74M
Other Stockholder Equity -47k 165k 129k -314k
Property, Plant, and Equipment 10.93M 9.63M 12.94M 51.59M
Total Current Assets 209.95M 128.57M 378.18M 218.51M
Net Tangible Assets 131.54M 97.79M 332.05M 252.56M
Net Receivables 2.49M 6.3M 5.56M 12.45M
Accounts Payable 3.06M 5.58M 5.54M 11.33M


Insider Transactions

Here are the insider transactions of stock shares related to Sutro Biopharma Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
CHUNG JANED2022-08-09Officer18.75k
VASQUEZ NICKID2022-07-12Officer3.25k
HALLAM TREVOR CD2022-04-14Officer3.75k
NEWELL WILLIAM JPurchase at price 7.75 per share.I2022-03-14Chief Executive Officer10k
ALBINI EDWARD CD2022-03-04Chief Financial Officer8.75k
NEWELL WILLIAM JD2022-03-04Chief Executive Officer18.75k
FITZPATRICK LINDA A.D2022-03-04Officer8.75k
HALLAM TREVOR CD2022-03-04Officer12.5k
MOLINA ARTUROD2022-03-04Officer12.5k
SHABBIR ANIKD2022-03-04Chief Technology Officer8.75k
VASQUEZ NICKID2022-03-04Officer5.5k
PETREE DANIEL HUNTERConversion of Exercise of derivative security at price 4.36 - 5.81 per share.D2022-02-08Director14.28k
ALBINI EDWARD CD2022-01-28Chief Financial Officer5.25k
NEWELL WILLIAM JD2022-01-28Chief Executive Officer13.75k
FITZPATRICK LINDA A.D2022-01-28Officer8.25k
HALLAM TREVOR CD2022-01-28Officer5.25k
MOLINA ARTUROD2022-01-28Officer5.25k
SHABBIR ANIKD2022-01-28Chief Technology Officer4.5k
VASQUEZ NICKID2022-01-28Officer2.5k
VASQUEZ NICKISale at price 18.62 per share.D2021-09-28Officer3.91k
ALBINI EDWARD CD2021-09-24Chief Financial Officer7.17k
NEWELL WILLIAM JD2021-09-24Chief Executive Officer25.25k
FITZPATRICK LINDA A.D2021-09-24Officer7.58k
HALLAM TREVOR CD2021-09-24Officer11.02k
MOLINA ARTUROD2021-09-24Officer8.61k
SHABBIR ANIKD2021-09-24Chief Technology Officer8.61k
VASQUEZ NICKID2021-09-24Officer5.97k
NEWELL WILLIAM JStock Gift at price 0.00 per share.D2021-07-01Chief Executive Officer104.66k
ALBINI EDWARD CD2021-01-29Chief Financial Officer5.25k
NEWELL WILLIAM JD2021-01-29Chief Executive Officer13.75k
FITZPATRICK LINDA A.D2021-01-29Officer8.25k
HALLAM TREVOR CD2021-01-29Officer5.25k
MOLINA ARTUROD2021-01-29Officer5.25k
SHABBIR ANIKD2021-01-29Chief Technology Officer4.5k
PETREE DANIEL HUNTERConversion of Exercise of derivative security at price 4.36 per share.D2021-01-26Director4.13k
HALLAM TREVOR CSale at price 25.68 - 26.10 per share.D2021-01-26Officer2.39k
HALLAM TREVOR CConversion of Exercise of derivative security at price 4.36 per share.D2021-01-26Officer2.39k
FITZPATRICK LINDA A.Conversion of Exercise of derivative security at price 4.36 per share.D2021-01-19Officer1.65k
HALLAM TREVOR CConversion of Exercise of derivative security at price 4.36 per share.D2021-01-14Officer19.41k
HALLAM TREVOR CSale at price 22.37 per share.D2020-12-28Officer2.39k
HALLAM TREVOR CConversion of Exercise of derivative security at price 4.36 per share.D2020-12-28Officer2.39k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Sutro Biopharma Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Sutro Biopharma Inc

Here is the result of two systematic investment strategies applied to Sutro Biopharma Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Sutro Biopharma Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Sutro Biopharma Inc:

Sutro Biopharma Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 59.88% on the backtest period.

Performance at glance

Performance

59.88 %

Latent gain

1044.3 $

Invested capital

1744.05 $

Annualized return

19.07 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Sutro Biopharma Inc

This is the result of two momentum investment strategies applied to Sutro Biopharma Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Sutro Biopharma Inc

The following chart shows all the entries opened by the momentum investment system on Sutro Biopharma Inc:

Sutro Biopharma Inc momentum entries
  • The first momentum investment strategy would give 85.28% of return on Sutro Biopharma Inc. That represents 4912.48$ of latent gain with 5760.17$ of employed capital.
  • The second momentum investment strategy would give 90.81% of return on Sutro Biopharma Inc. That represents 2956.08$ of latent gain with 3255.21$ of employed capital.
Performance at glance (1Q Momentum)

Performance

85.28 %

Latent gain

4912.48 $

Invested capital

5760.17 $

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

90.81 %

Latent gain

2956.08 $

Invested capital

3255.21 $

Annualized return

34.14 %

Momentum equity curve on Sutro Biopharma Inc

The following chart shows the equity curve of the two momentum strategies applied to Sutro Biopharma Inc:

Sutro Biopharma Inc momentum equity

Note: the dividends potentially given by Sutro Biopharma Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Sutro Biopharma Inc

The following chart shows the employed capital evolution of the two momentum strategies on Sutro Biopharma Inc since the beginning:

Sutro Biopharma Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Sutro Biopharma Inc

Buy the dip entry openings on Sutro Biopharma Inc

Sutro Biopharma Inc

The performance achieved by the robo-advisor on Sutro Biopharma Inc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows Sutro Biopharma Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Sutro Biopharma Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

0.0 %

Equity curve of the strategy applied to Sutro Biopharma Inc

The following chart shows the result of the investment strategy applied to Sutro Biopharma Inc:

Sutro Biopharma Inc

Note: the dividends potentially given by Sutro Biopharma Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Sutro Biopharma Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Sutro Biopharma Inc:

Sutro Biopharma Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Sutro Biopharma Inc

In this section, I will compare the three previous investment strategies applied to Sutro Biopharma Inc.

Equity curve comparison on Sutro Biopharma Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Sutro Biopharma Inc investment strategy comparison

Employed capital comparison on Sutro Biopharma Inc

Sutro Biopharma Inc investment comparison

Performance comparison on Sutro Biopharma Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 59.88% 1044.3$ 1744.05$ 19.07%
Momentum 1 quarter 85.28% 4912.48$ 5760.17$ 29.41%
Momentum 2 quarters 90.81% 2956.08$ 3255.21$ 34.14%
Non-directional 0% 0.0$ 0.0$ 0.0%
Annualized return comparison

Automatic investment

19.07 %

Momentum 1Q

34.14 %

Momentum 2Q

34.14 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Sutro Biopharma Inc:

Positive correlations

Most correlated stocks this year

  • Sutro Biopharma Inc

  • Most correlated stocks last 3 months

  • Sutro Biopharma Inc

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • Inovio Pharmaceuticals Inc
  • Masimo Corp
  • Newmont Corp

  • Note: The algorithm computes the probability of correlation between Sutro Biopharma Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Sutro Biopharma Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Sutro Biopharma Inc
    Country United States
    City South San Francisco
    Address 111 Oyster Point Boulevard
    Phone 650 881 6500
    Website www.sutrobio.com
    FullTime employees 259
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker STRO
    Market www.nasdaq.com

    Sutro Biopharma Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown